ProQR Therapeutics NV
PRQR2.140USD
-0.070-3.17%
收盤 12/22, 16:00（美東）報價延遲15分鐘
230.50M總市值
虧損本益比TTM
關於 ProQR Therapeutics NV 公司
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV簡介
公司代碼PRQR
公司名稱ProQR Therapeutics NV
上市日期Sep 18, 2014
CEOde Boer (Daniel Anton)
員工數量166
證券類型Ordinary Share
年結日Sep 18
公司地址Zernikedreef 9
城市LEIDEN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Netherlands
郵編2333 CK
電話31881667000
網址https://www.proqr.com/
公司代碼PRQR
上市日期Sep 18, 2014
CEOde Boer (Daniel Anton)
ProQR Therapeutics NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.42%
其他
56.26%
持股股東
持股股東
佔比
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.42%
其他
56.26%
股東類型
持股股東
佔比
Hedge Fund
18.45%
Corporation
16.04%
Family Office
13.60%
Investment Advisor
9.89%
Investment Advisor/Hedge Fund
5.04%
Research Firm
3.13%
Individual Investor
2.00%
Bank and Trust
0.03%
其他
31.83%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
111
41.68M
39.56%
-4.38M
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Eli Lilly and Company
16.90M
16.04%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
14.33M
13.6%
+2.13M
+17.44%
Sep 29, 2025
Adage Capital Management, L.P.
6.60M
6.27%
-1.50M
-18.52%
Jun 30, 2025
Privium Fund Management BV
5.00M
4.74%
+11.93K
+0.24%
Jun 30, 2025
Affinity Asset Advisors LLC
3.50M
3.32%
+215.00K
+6.55%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.06M
2.91%
+1.70M
+124.72%
Jun 30, 2025
abrdn Inc.
1.85M
1.76%
--
--
Jun 30, 2025
Sio Capital Management, LLC
2.08M
1.97%
+20.55K
+1.00%
Jun 30, 2025
Kynam Capital Management LP
1.65M
1.57%
-100.54K
-5.75%
Jun 30, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Avantis International Small Cap Equity ETF
0.01%
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
佔比0.01%
Avantis International Small Cap Value ETF
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
ProQR Therapeutics NV的前五大股東是誰？
ProQR Therapeutics NV的前五大股東如下：
Eli Lilly and Company持有股份：16.90M佔總股份比例：16.04%。
Van Herk Investments持有股份：14.33M佔總股份比例：13.60%。
Adage Capital Management, L.P.持有股份：6.60M佔總股份比例：6.27%。
Privium Fund Management BV持有股份：5.00M佔總股份比例：4.74%。
Affinity Asset Advisors LLC持有股份：3.50M佔總股份比例：3.32%。
Eli Lilly and Company持有股份：16.90M佔總股份比例：16.04%。
Van Herk Investments持有股份：14.33M佔總股份比例：13.60%。
Adage Capital Management, L.P.持有股份：6.60M佔總股份比例：6.27%。
Privium Fund Management BV持有股份：5.00M佔總股份比例：4.74%。
Affinity Asset Advisors LLC持有股份：3.50M佔總股份比例：3.32%。
ProQR Therapeutics NV的前三大股東類型是什麼？
ProQR Therapeutics NV 的前三大股東類型分別是：
Eli Lilly and Company
Van Herk Investments
Adage Capital Management, L.P.
Eli Lilly and Company
Van Herk Investments
Adage Capital Management, L.P.
有多少機構持有ProQR Therapeutics NV(PRQR)的股份？
截至2025Q3，共有111家機構持有ProQR Therapeutics NV的股份，合計持有的股份價值約為41.68M，占公司總股份的39.56% 。與2025Q2相比，機構持股有所增加，增幅為-18.39%。
哪個業務部門對ProQR Therapeutics NV的收入貢獻最大？
在--，--業務部門對ProQR Therapeutics NV的收入貢獻最大，創收--，占總收入的--% 。
